ILUMINOS THERAPEUTICS LLC

Tucson, AZ · Biotech · Private

Selective DYRK1A inhibitor small molecule (Dyr533) for Down syndrome cognitive decline

Grants
$3.9M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$498,634
Federal grantDepartment of Health and Human Services · Phase I · Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$498,634
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,496,403
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,428,499
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2925NewAmsterdam Pharma——
2926TRPBLUE, INC.——
2927Senotrac Biotechnology LLC——
2928ILUMINOS THERAPEUTICS LLC——
2929LIFEPHARMS, INC.——
2930Nautilus Biotechnology——
2931Annias Immunotherapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.